- Home
- STRO vs NFE Comparison
STRO vs NFE Comparison
Compare STRO & NFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STRO | NFE |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil/Gas Transmission |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.8M | 324.4M |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | STRO | NFE |
|---|---|---|
| Price | $16.91 | $13.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $31.33 | $5.50 |
| AVG Volume (30 Days) | 207.3K | ★ 3.1M |
| Earning Date | 05-11-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $38,419,000.00 | ★ $1,504,037,000.00 |
| Revenue This Year | N/A | $110.34 |
| Revenue Next Year | N/A | $3.54 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.72 | $0.23 |
| 52 Week High | $43.85 | $3.08 |
Technical Indicators
Market Signals| Indicator | STRO | NFE |
|---|---|---|
| Relative Strength Index (RSI) | 26.11 | 99.47 |
| Support Level | $10.34 | $0.65 |
| Resistance Level | $17.33 | N/A |
| Average True Range (ATR) | 0.99 | 0.24 |
| MACD | -0.24 | 0.87 |
| Stochastic Oscillator | 9.16 | 82.19 |
Price Performance
Historical ComparisonAbout STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About NFE New Fortress Energy Inc.
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.